Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
In this study, researchers propose a unique (individualized) approach to steroid treatment seeking to give the right dose of steroid to the right patient and at the right time. This study seeks to compare usual care to an individualized steroid dosing strategy by testing a marker of inflammation in the blood called C- reactive protein (CRP). The overall goal is to reduce an individual's exposure to steroids and the risk of potential side effects thereby increasing the potential benefit of using steroids to control inflammation in pneumonia.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Usual Care Group | No Intervention | Usual care as determined by the patient's primary team. Initiation and daily dosing of corticosteroid treatment will be based on clinicians' preference and clinicians. | |
| Individualized dosing strategy | Experimental | Biomarker guided corticosteroid use. Initiation of corticosteroid will be recommended based on the an individual treatment rule (ITR) and subsequent dosing of corticosteroid will be recommended based on daily CRP values till CRP <50 mg/L (according to a prespecified C-reactive protein-guided dosing algorithm). Corticosteroid dose and duration were determined by serial CRP measurements The approved protocol included CRP-guided corticosteroid dosing as a prespecified contingency strategy if a clinically actionable individualized treatment rule could not be developed. The trial therefore proceeded with the CRP-guided corticosteroid strategy |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Dexamethasone | Drug | Administered intravenously or orally based on daily CRP values and CRP corticosteroid dosing algorithm |
|
| Measure | Description | Time Frame |
|---|---|---|
| Adherence to individual treatment rule and CRP-guided corticosteroid treatment | Number of eligible subjects that adhered to the timely initiation and daily corticosteroid treatment | First 5 days of hospitalization or until hospital discharge (whichever is sooner) |
| Measure | Description | Time Frame |
|---|---|---|
| In-hospital Disease Progression | Progression on the WHO clinical progression scale from 4 to 10 | First 5 days of hospitalization or until hospital discharge (whichever is sooner) |
| Need for Advanced Respiratory Support |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Yewande Odeyemi, MBBS | Mayo Clinic | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mayo Clinic Rochester | Rochester | Minnesota | 55905 | United States |
Not provided
| Label | URL |
|---|---|
| Mayo Clinic Clinical Trials | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D011014 | Pneumonia |
| ID | Term |
|---|---|
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D003907 | Dexamethasone |
| ID | Term |
|---|---|
| D011246 | Pregnadienetriols |
| D011245 | Pregnadienes |
| D011278 | Pregnanes |
| D013256 | Steroids |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Number of participants to require use of advanced respiratory support (high flow nasal cannula, non-invasive positive pressure ventilation and invasive ventilation)
| First 5 days of hospitalization or until hospital discharge (whichever is sooner) |
| Advanced respiratory support free days | Number of days without need for high flow nasal cannula, non-invasive positive pressure ventilation and invasive ventilation within 28 days of need for support. Assign 0 if death occurs with 28 days. | First 5 days of hospitalization or until hospital discharge (whichever is sooner) |
| ICU and hospital free days | Number of days patient was alive outside the ICU or hospital within the first 28 days of admission | First 5 days of hospitalization or until hospital discharge (whichever is sooner) |
| Mortality | Number of subject deaths | First 5 days of hospitalization or until hospital discharge (whichever is sooner) |
| D000072473 |
| Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
| D013259 | Steroids, Fluorinated |